[
    [
        {
            "time": "2018-01-03",
            "original_text": "AbbVie Appears Ready to Start a New Advance at Any Time",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Advance",
                    "Ready"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Appears Ready to Start a New Advance at Any Time",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Lilly's Taltz Positive in Phase III Label Expansion Study",
            "features": {
                "keywords": [
                    "Lilly",
                    "Taltz",
                    "Phase III",
                    "Positive"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Taltz Positive in Phase III Label Expansion Study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "MTUM, BA, ABBV, C: ETF Inflow Alert",
            "features": {
                "keywords": [
                    "ETF",
                    "Inflow",
                    "MTUM",
                    "BA",
                    "ABBV",
                    "C"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "healthcare",
                    "industrials"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "MTUM, BA, ABBV, C: ETF Inflow Alert",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Inflammation",
                    "Immunology",
                    "Portfolio",
                    "Performances"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Lilly's Taltz Positive in Phase III Label Expansion Study",
            "features": {
                "keywords": [
                    "Lilly",
                    "Taltz",
                    "Phase III",
                    "Positive"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Taltz Positive in Phase III Label Expansion Study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "3 Top Stocks You Can Buy and Hold for the Next Decade",
            "features": {
                "keywords": [
                    "Top Stocks",
                    "Buy",
                    "Hold",
                    "Decade"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Top Stocks You Can Buy and Hold for the Next Decade",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17",
            "features": {
                "keywords": [
                    "Bristol-Myers Squibb",
                    "Orencia",
                    "Brands",
                    "4Q17"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "3 Dividend Stocks for In-the-Know Investors",
            "features": {
                "keywords": [
                    "Dividend Stocks",
                    "Investors"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Dividend Stocks for In-the-Know Investors",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Is Now a Good Time to Buy AbbVie?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Buy"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is Now a Good Time to Buy AbbVie?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]